{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:02:47Z","timestamp":1760061767673},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T00:00:00Z","timestamp":1273708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T00:00:00Z","timestamp":1273708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1038\/gt.2010.76","type":"journal-article","created":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T21:06:20Z","timestamp":1273784780000},"page":"1234-1243","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: anti-CD20Fab-LDM"],"prefix":"10.1038","volume":"17","author":[{"given":"C","family":"Xin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Ming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Shenghua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Qingfang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Hongxing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Yuanfu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Dongmei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Juanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Yingdai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Lianfang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Rongguang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Zhenping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Jianxiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Chunzheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Dongsheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Yongsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,13]]},"reference":[{"key":"BFgt201076_CR1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/01.moh.0000141927.77393.39","volume":"11","author":"AA van de Loosdrecht","year":"2004","unstructured":"van de Loosdrecht AA, Huijgens PC, Ossenkoppele GJ . Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin's lymphoma. Curr Opin Hematol 2004; 11: 419\u2013425.","journal-title":"Curr Opin Hematol"},{"key":"BFgt201076_CR2","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490\u20131496.","journal-title":"Clin Cancer Res"},{"key":"BFgt201076_CR3","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","volume":"19","author":"EL Sievers","year":"2001","unstructured":"Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244\u20133254.","journal-title":"J Clin Oncol"},{"key":"BFgt201076_CR4","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.7164\/antibiotics.41.1575","volume":"41","author":"JL Hu","year":"1988","unstructured":"Hu JL, Xue YC, Xie MY, Zhang R, Otani T, Minami Y et al. A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot (Tokyo) 1988; 41: 1575\u20131579.","journal-title":"J Antibiot (Tokyo)"},{"key":"BFgt201076_CR5","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.7164\/antibiotics.41.1580","volume":"41","author":"T Otani","year":"1988","unstructured":"Otani T, Minami Y, Marunaka T, Zhang R, Xie MY . A new macromolecular antitumor antibiotic, C-1027. II. Isolation and physico-chemical properties. J Antibiot (Tokyo) 1988; 41: 1580\u20131585.","journal-title":"J Antibiot (Tokyo)"},{"key":"BFgt201076_CR6","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.7164\/antibiotics.42.1294","volume":"42","author":"YS Zhen","year":"1989","unstructured":"Zhen YS, Ming XY, Yu B, Otani T, Saito H, Yamada Y . A new macromolecular antitumor antibiotic, C-1027. III. Antitumor activity. J Antibiot (Tokyo) 1989; 42: 1294\u20131298.","journal-title":"J Antibiot (Tokyo)"},{"key":"BFgt201076_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/BF00689274","volume":"27","author":"YJ Xu","year":"1990","unstructured":"Xu YJ, Li DD, Zhen YS . Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human hepatoma BEL-7402 cells. Cancer Chemother Pharmacol 1990; 27: 41\u201346.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFgt201076_CR8","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.3748\/wjg.v11.i26.3980","volume":"11","author":"YH Huang","year":"2005","unstructured":"Huang YH, Shang BY, Zhen YS . Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule. World J Gastroenterol 2005; 11: 3980\u20133984.","journal-title":"World J Gastroenterol"},{"key":"BFgt201076_CR9","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1021\/bi00185a036","volume":"33","author":"YJ Xu","year":"1994","unstructured":"Xu YJ, Zhen YS, Goldberg IH . C1027 chromophore, a potent new enediyne antitumor antibiotic, induces sequence-specific double-strand DNA cleavage. Biochemistry 1994; 33: 5947\u20135954.","journal-title":"Biochemistry"},{"key":"BFgt201076_CR10","doi-asserted-by":"publisher","first-page":"5344","DOI":"10.1158\/0008-5472.CAN-05-0015","volume":"65","author":"MM McHugh","year":"2005","unstructured":"McHugh MM, Gawron LS, Matsui S, Beerman TA . The antitumor enediyne C-1027 alters cell cycle progression and induces chromosomal aberrations and telomere dysfunction. Cancer Res 2005; 65: 5344\u20135351.","journal-title":"Cancer Res"},{"key":"BFgt201076_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1006\/bbrc.1995.1329","volume":"208","author":"B Jiang","year":"1995","unstructured":"Jiang B, Li DD, Zhen YS . Induction of apoptosis by enediyne antitumor antibiotic C1027 in HL-60 human promyelocytic leukemia cells. Biochem Biophys Res Commun 1995; 208: 238\u2013244.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFgt201076_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF02900598","volume":"46","author":"ZZ Lai","year":"2001","unstructured":"Lai ZZ, Xiong DS, Fan DM, Xu YF, Liu HZ, Peng H et al. Efficacy of anti-CD20 chimeric Fab\u2032 fragment on proliferation of B lymphoma cells. Chin Sci Bull 2001; 46: 5.","journal-title":"Chin Sci Bull"},{"key":"BFgt201076_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7164\/antibiotics.43.417","volume":"43","author":"Y Sugimoto","year":"1990","unstructured":"Sugimoto Y, Otani T, Oie S, Wierzba K, Yamada Y . Mechanism of action of a new macromolecular antitumor antibiotic, C-1027. J Antibiot (Tokyo) 1990; 43: 417\u2013421.","journal-title":"J Antibiot (Tokyo)"},{"key":"BFgt201076_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.exphem.2006.02.015","volume":"34","author":"L Fischer","year":"2006","unstructured":"Fischer L, Penack O, Gentilini C, Nogai A, Muessig A, Thiel E et al. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol 2006; 34: 753\u2013759.","journal-title":"Exp Hematol"},{"key":"BFgt201076_CR15","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-06-1860","volume":"13","author":"JG Berdeja","year":"2007","unstructured":"Berdeja JG, Hess A, Lucas DM, O\u2032Donnell P, Ambinder RF, Diehl LF et al. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res 2007; 13: 2392\u20132399.","journal-title":"Clin Cancer Res"},{"key":"BFgt201076_CR16","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","volume":"172","author":"AD Kennedy","year":"2004","unstructured":"Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004; 172: 3280\u20133288.","journal-title":"J Immunol"},{"key":"BFgt201076_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1023\/A:1006341717398","volume":"18","author":"RO Dillman","year":"1999","unstructured":"Dillman RO . Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999; 18: 465\u2013471.","journal-title":"Cancer Metastasis Rev"},{"key":"BFgt201076_CR18","doi-asserted-by":"publisher","first-page":"7435","DOI":"10.4049\/jimmunol.177.10.7435","volume":"177","author":"ME Williams","year":"2006","unstructured":"Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006; 177: 7435\u20137443.","journal-title":"J Immunol"},{"key":"BFgt201076_CR19","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.4049\/jimmunol.179.6.4263","volume":"179","author":"Y Li","year":"2007","unstructured":"Li Y, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, Taylor RP . Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol 2007; 179: 4263\u20134271.","journal-title":"J Immunol"},{"key":"BFgt201076_CR20","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.4049\/jimmunol.176.4.2600","volume":"176","author":"PV Beum","year":"2006","unstructured":"Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP . The shaving reaction: rituximab\/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006; 176: 2600\u20132609.","journal-title":"J Immunol"},{"key":"BFgt201076_CR21","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1158\/1535-7163.1693.3.12","volume":"3","author":"MR Smith","year":"2004","unstructured":"Smith MR, Jin F, Joshi I . Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse\/human lymphoma xenografts. Mol Cancer Ther 2004; 3: 1693\u20131699.","journal-title":"Mol Cancer Ther"},{"key":"BFgt201076_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.2008.07353.x","volume":"143","author":"B Pro","year":"2008","unstructured":"Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma. Br J Haematol 2008; 143: 355\u2013360.","journal-title":"Br J Haematol"},{"key":"BFgt201076_CR23","first-page":"250","volume":"38","author":"HZ Liu","year":"2003","unstructured":"Liu HZ, Li DD, Zhen YS, Shao RG . Potentiation and mechanism of cisplatin-induced apoptosis by lidamycin in human hepatoma BEL-7402 cells]. Yao Xue Xue Bao 2003; 38: 250\u2013254.","journal-title":"Yao Xue Xue Bao"},{"key":"BFgt201076_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1006\/jmbi.2001.4621","volume":"309","author":"T Tanaka","year":"2001","unstructured":"Tanaka T, Fukuda-Ishisaka S, Hirama M, Otani T . Solution structures of C-1027 apoprotein and its complex with the aromatized chromophore. J Mol Biol 2001; 309: 267\u2013283.","journal-title":"J Mol Biol"},{"key":"BFgt201076_CR25","first-page":"3209","volume":"58","author":"Z Zhu","year":"1998","unstructured":"Zhu Z, Rockwell P, Lu D, Kotanides H, Pytowski B, Hicklin DJ et al. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res 1998; 58: 3209\u20133214.","journal-title":"Cancer Res"},{"key":"BFgt201076_CR26","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/nbt1320","volume":"25","author":"XQ Qiu","year":"2007","unstructured":"Qiu XQ, Wang H, Cai B, Wang LL, Yue ST . Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat Biotechnol 2007; 25: 921\u2013929.","journal-title":"Nat Biotechnol"},{"key":"BFgt201076_CR27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.cbpa.2003.08.007","volume":"7","author":"JV Frangioni","year":"2003","unstructured":"Frangioni JV . In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 2003; 7: 626\u2013634.","journal-title":"Curr Opin Chem Biol"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt201076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt201076","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt201076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T05:14:51Z","timestamp":1685596491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt201076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,13]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["BFgt201076"],"URL":"https:\/\/doi.org\/10.1038\/gt.2010.76","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,13]]},"assertion":[{"value":"30 November 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}